Licensed by the Securities and Commodities Authority (SCA) and compliant across multiple international jurisdictions, Skyriss is gaining momentum for its seamless trading experience, advanced infrastructure, and commitment to transparency. The platform offers traders access to a wide range of global markets, including forex, commodities, indices, shares, and crypto CFDs, all through a unified, performance-driven ecosystem.

“At Skyriss, we didn’t set out to build just another trading platform — we built a trading experience,” said, Director at Skyriss. “Today’s traders want more than just access. They want speed, simplicity, and trust. That’s what we deliver — and why traders across the globe are choosing us.”

A Brokerage Built for the Modern Trader

Skyriss operates on a core philosophy of “Limitless Possibilities,” combining instant account onboarding, low-latency execution, and a user-first interface that gives traders unmatched control over their portfolios. Whether trading on desktop or mobile, users benefit from an intuitive environment designed to reduce friction and maximize performance.

The company’s institutional-grade infrastructure has made it a popular choice among retail and professional traders seeking a reliable, regulated CFD trading platform — especially as global demand for online financial services continues to rise.

Why Skyriss Is Gaining Global Attention

• Regulated Multi-Asset Brokerage: Fully licensed by the SCA and compliant across jurisdictions
• Unified Platform: Access major global markets from a single account — forex, shares, indices, commodities, and crypto CFDs
• Fastest Onboarding in the Industry: Traders can open an account and start trading within minutes
• Institutional-Grade Technology: Low-latency trade execution built for serious strategies
• Mobile-First Design: A seamless user experience across all devices
• Client-Centric Model: Strong support and protection frameworks with multilingual assistance

Growing Momentum Across Emerging Markets

Skyriss is also experiencing strong growth across India, Southeast Asia, and Africa, as traders in emerging markets turn to digital platforms that prioritize compliance, speed, and usability. The platform’s mobile-first approach and quick onboarding process make it especially appealing to a new generation of retail traders in the region.

“As we expand into emerging markets, our goal is to provide every trader — regardless of location — with tools and infrastructure previously reserved for institutions,” added, the Director.

About Skyriss

Skyriss is a regulated multi-asset CFD brokerage based in Dubai, offering access to global financial markets including forex, indices, commodities, shares, and crypto CFDs. Built with cutting-edge technology and licensed by the Securities and Commodities Authority (SCA), Skyriss empowers traders with speed, simplicity, and transparency — all through one secure platform.

Open an account today. It is that simple.

www.skyriss.com

Sphere Bio, formerly known as Sphere Fluidics, is widely recognized for its innovations in single-cell and picodroplet microfluidics. Their technologies enable ultra-high-throughput analysis, sorting, and isolation of individual cells – critical for applications such as antibody discovery, cell line development, and advanced cell therapy research. These platforms are currently used by leading pharma companies and research institutions around the world to enhance the speed and accuracy of biologic development.

For Premas Life Sciences, this partnership is a natural extension of its mission to democratize access to advanced life science tools. Over the last 18 years, PLS has built a strong legacy of introducing globally benchmarked technologies to India’s scientific ecosystem – spanning genomics, proteomics, bioinformatics, and diagnostics. Their ability to not only introduce but also embed technologies through technical training, application support, and long-term scientific partnerships makes them uniquely positioned to amplify the impact of Sphere Bio’s offerings.

“India is entering a new era of biomedical innovation, with increased investments in biosimilars, vaccines, and cell and gene therapies. This collaboration with Sphere Bio allows us to deliver the kind of scientific capabilities that can transform how research is done in this region–faster, more precisely, and with greater reproducibility. With the government’s strong push through initiatives like the Bio-E3 policy, PRIP scheme, and its vision for bio foundries, we believe technologies like Sphere Bio’s Cyto-Mine® will play a crucial role in accelerating antibody discovery and cell line development, further strengthening the ‘Made in India’ biotech ecosystem. We’re excited to co-create a future where access to such platforms is not a barrier but a baseline.” said Praveen Gupta, Managing Director of Premas Life Sciences.

Sphere Bio echoed this optimism. “We see South Asia as a region with enormous scientific potential. Our partnership with Premas is about more than market access – it’s about long-term impact. Premas brings deep local understanding, technical know-how, and a genuine commitment to enabling discovery. Together, we aim to catalyse the next wave of breakthroughs in biologics and personalized medicine.” said Dale Levitzke, CEO of Sphere Bio

“Our partnership with Premas Life Sciences is a key milestone in our mission to make cutting-edge single-cell technologies more accessible across the APAC region. India and Bangladesh represent rapidly growing innovation hubs, and we see immense potential in empowering local researchers with tools that meet global standards. Premas brings deep market understanding, strong scientific engagement, and a track record of successful technology integration–making them an ideal partner to drive regional adoption and impact.” said Jay Manikandan, VP Commercial (APAC), Sphere Bio

This alliance comes at a pivotal time, as the biotech landscape in India and Bangladesh rapidly evolves with government backing, rising R&D investment, and a growing scientific workforce. As demand for next-gen therapeutics increases, so does the need for high-resolution, scalable tools–precisely what Sphere Bio delivers. Together, Premas and Sphere Bio are building a scientific bridge between global innovation and regional potential. Beyond product access, the partnership offers localized support, training, and tailored solutions aligned with international standards. It sets a new benchmark for how advanced technologies can be effectively introduced and scaled in emerging biotech markets.